According to internal media reports, with the conclusion of the recent national organization pharmaceutical joint procurement conference on the tenth batch of national pharmaceutical collection, the work on reporting the tenth batch of national pharmaceutical collection officially started today (18th).

Shanxi Province Pharmaceutical Centralized Competitive Bidding Procurement Network issued a notice on submitting the demand quantity for the tenth batch of national organizational pharmaceutical centralized procurement on Wednesday (16th). The deadline for medical institutions to submit is from October 18 to 28, using the online direct reporting method. When the reported quantity of medical institutions is less than 80% of their historical procurement volume, an explanation is required. Medical institutions with historical procurement volumes who do not participate in reporting will be closely monitored in later execution.

For varieties that show an increasing trend in usage due to being newly included in the medical insurance catalog and having an elevated position in guidelines for 2022 and 2023, the requirement is to strive to achieve 100% of the historical procurement volume. To align with the strengthened rational drug use management by the Health Department, there is no lower limit for medical institutions to report on varieties listed in the 'National Key Monitoring Rational Drug Catalog.' Antibiotics may appropriately reduce the reported quantity based on 80% of historical procurement volume.

In addition, after assessing the savings from centralized procurement of medical insurance funds, a certain proportion will be retained as the balance for medical institutions, and the calculation base of the balance retention fund is directly related to the reported quantity. However, the reported quantity catalog is not equal to the final centralized procurement catalog, and adjustments may still be made based on actual circumstances after reporting.

Based on this, the tenth batch of national pharmaceutical collection includes 62 varieties with 263 specifications, reaching a new high in the history of national pharmaceutical collections, with injectables accounting for 35 varieties, or 56.45%.

Looking at the production enterprises, Qilu Pharmaceutical, Sichuan Kelun Pharmaceutical (002422.SZ), CSPC Pharma (01093.HK), and Chengdu Betta continue to lead as the leading companies.